RT Journal Article
T1 Choroidal thickness and granulocyte colony-stimulating factor in tears improve the prediction model for coronary artery disease.
A1 Romero-Trevejo, José Lorenzo
A1 Fernández-Romero, Lourdes
A1 Delgado, Josué
A1 Muñoz-García, Erika
A1 Sánchez-Pérez, Andrés
A1 Murri, Mora
A1 Gutiérrez-Bedmar, Mario
A1 Jiménez-Navarro, Manuel Francisco
K1 Cardiovascular prevention
K1 Choroidal thickness
K1 Coronary artery disease
K1 Granulocyte colony-stimulating factor
K1 Predictive model
K1 ROC curves
AB Coronary artery disease (CAD) detection in asymptomatic patients still remains controversial. The aim of our study was to evaluate the usefulness of ophthalmologic findings as predictors of the presence of CAD when added to cardiovascular classic risk factors (CRF) in patients with acute coronary cardiopathy suspicion. After clinical stabilization, 96 patients with acute coronary cardiopathy suspicion were selected and divided in two groups: 69 patients with coronary lesions and 27 patients without coronary lesions. Their 192 eyes were subjected to a complete routine ophthalmologic examination. Samples of tear fluid were also collected to be used in the detection of cytokines and inflammatory mediators. Logistic regression models, receiver operating characteristic curves and their area under the curve (AUC) were analysed. Suggestive predictors were choroidal thickness (CT) (OR: 1.02, 95% CI 1.01-1.03) and tear granulocyte colony-stimulating factor (G-CSF) (OR: 0.97, 95% CI 0.95-0.99). We obtained an AUC of 0.9646 (95% CI 0.928-0.999) when CT and tear G-CSF were added as independent variables to the logistic regression model with cardiovascular CRF: sex, age, diabetes, high blood pressure, hypercholesterolemia, smoking habit and obesity. This AUC was significantly higher (p = 0.003) than the prediction derived from the same logistic regression model without CT and tear G-CSF (AUC = 0.828, 95% CI 0.729-0.927). CT and tear G-CSF improved the predictive model for CAD when added to cardiovascular CRF in our sample of symptomatic patients. Subsequent studies are needed for validation of these findings in asymptomatic patients.
YR 2022
FD 2022-06-09
LK http://hdl.handle.net/10668/20320
UL http://hdl.handle.net/10668/20320
LA en
DS RISalud
RD Apr 17, 2025